Solution for Type 1A Endoleaks After Abdominal Endoprosthesis

Proximal type 1 endoleaks after endovascular abdominal aortic aneurysmal repair are challenging to solve, with no existing consensus on the proper solution.

This work compared the most radical solution to the problem vs. a more conservative—though still challenging—option.

The first one was the surgical explantation of the endoprosthesis with aortic reconstruction, while the more “conservative” one was a customized fenestrated endoprosthesis.

This retrospective analysis included patients who, between 2009 and 2018, underwent one of the aforementioned two options to resolve a type 1A endoleak. Operators made the decision based on anatomy (fenestrated prosthesis eligibility), sac growth rate, and emergency or symptomatic presentation.

There were only 59 patients found who met these criteria in the almost 10 years included, but this is very useful information because of the scarcity of data and the risks of both strategies.


Read also: Data that Can Change TAVR and SAVR Strategy.


Endoprosthesis explantation and aortic reconstruction were performed in 26 patients, while implantation of a customized fenestrated endoprosthesis was conducted in 33 cases.

Both groups were similar in age and comorbidities at the time of procedure. Mean time between original endoprosthesis and new procedure was 60.4 months (34-85 months).

The maximum aneurysm diameter was greater in the surgical explantation and reconstruction group (86 mm vs. 70 mm, p = 0.008)

Secondary interventions at 30 days (11.5% vs. 9.1%) and mortality (3.8% vs. 3.3%) were similar between groups.


Read also: Revascularization Is Needed Before TAVR.


The rates of major adverse events, as defined by the Society for Vascular Surgery guidelines, were lower in the groups treated with fenestrated endoprosthesis (2.4% vs. 13.6%; p = 0.016).

After a year of follow-up, survival was similar in both groups (84% vs. 86.6%).

Conclusion

Both endoprosthesis explantation with aorta reconstruction and fenestrated endoprosthesis implantation are satisfactory solutions in high-volume and experienced centers for the treatment of type 1A leaks.

Fenestrated prosthesis has a lower initial morbidity, but its elaboration takes time, which many patients do not have. In these cases, surgery is an excellent choice.

Original Title: After EVAR by Explantation or Custom Made Fenestrated Endovascular Aortic Aneurysm Repair.

Reference: Benoit Doumenc et al. Eur J Vasc Endovasc Surg. 2021. Online ahead of print doi: 10.1016/j.ejvs.2020.10.033.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....